VRC-HIVMAB091-00-AB (N6LS)

VRC-HIVMAB091-00-AB · National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for VRC-HIVMAB091-00-AB (N6LS), covering 2023-09-21 to 2023-09-21. Get the full timeline:

Most recent: Clinical Trial Update: Phase I, Open-Label, Dose-Escalation Study of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) [Phase 1]

See pricing